UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future

Journal of clinical pharmacology, 2017-10, Vol.57 (S10), p.S11-S25

2017

Volltextzugriff (PDF)

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager

PloS one, 2024-05, Vol.19 (5), p.e0300174

2024

Volltextzugriff (PDF)

Dynamic Cell and Microparticle Control via Optoelectronic Tweezers

Journal of microelectromechanical systems, 2007-06, Vol.16 (3), p.491-499

2007

Volltextzugriff (PDF)

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

Drug metabolism and disposition, 2014-11, Vol.42 (11), p.1914-1920

2014

Volltextzugriff (PDF)

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Journal of clinical pharmacology, 2007-07, Vol.47 (7), p.834-840

2007

Volltextzugriff (PDF)

Kinetic feasibility of nitroxyl reduction by physiological reductants and biological implications

Free radical biology & medicine, 2009-10, Vol.47 (8), p.1130-1139

2009

Volltextzugriff (PDF)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Journal of clinical pharmacology, 2017-09, Vol.57 (9), p.1148-1158

2017

Volltextzugriff (PDF)

Nitric Oxide is Consumed, Rather Than Conserved, by Reaction with Oxyhemoglobin under Physiological Conditions

Proceedings of the National Academy of Sciences - PNAS, 2002-08, Vol.99 (16), p.10341-10346

2002

Volltextzugriff (PDF)

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Clinical cancer research, 2012, Vol.18 (1), p.248-255

2012

Volltextzugriff (PDF)

Modulation of Nitric Oxide Bioavailability by Erythrocytes

Proceedings of the National Academy of Sciences - PNAS, 2001-09, Vol.98 (20), p.11771-11776

2001

Volltextzugriff (PDF)

Nitric Oxide Reaction with Red Blood Cells and Hemoglobin under Heterogeneous Conditions

Proceedings of the National Academy of Sciences - PNAS, 2002-05, Vol.99 (11), p.7763-7768

2002

Volltextzugriff (PDF)

Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier

Biochimica et biophysica acta, 2005-05, Vol.1723 (1), p.135-142

2005

Volltextzugriff (PDF)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.696-705

2016

Volltextzugriff (PDF)

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

Journal of clinical pharmacology, 2013-08, Vol.53 (8), p.866-877

2013

Volltextzugriff (PDF)

Regulation of Nitric Oxide Consumption by Hypoxic Red Blood Cells

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (21), p.12504-12509

2003

Volltextzugriff (PDF)

Nitric Oxide Metabolism in Adults With Cyanotic Congenital Heart Disease

The American journal of cardiology, 2007-03, Vol.99 (5), p.691-695

2007

Volltextzugriff (PDF)

Antioxidant actions of nitroxyl (HNO)

Free radical biology & medicine, 2007-02, Vol.42 (4), p.482-491

2007

Volltextzugriff (PDF)

Characterizing the PK/PD relationship for inhibition of capsaicin‐induced dermal vasodilatation by MK‐3207, an oral calcitonin gene related peptide receptor antagonist

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.831-837

2015

Volltextzugriff (PDF)

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

European journal of drug metabolism and pharmacokinetics, 2018-06, Vol.43 (3), p.347-354

2018

Volltextzugriff (PDF)

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults

Journal of clinical pharmacology, 2010-12, Vol.50 (12), p.1367-1376

2010

Volltextzugriff (PDF)

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

Headache, 2012-04, Vol.52 (4), p.625-635

2012

Volltextzugriff (PDF)

Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

Asia-Pacific journal of clinical oncology, 2010-03, Vol.6 (1), p.42-48

2010

Volltextzugriff (PDF)

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

Anesthesia and analgesia, 2009-08, Vol.109 (2), p.418-425

2009

Volltextzugriff (PDF)

Power grid aware timing analysis using S-parameter

International journal of electronics, 2010-07, Vol.97 (7), p.759-772

2010

Volltextzugriff (PDF)

1 – 25 von 2.393

Suche als RSS-Feed

Aktive Filter

SprachePersisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.171)
Mit Volltextzugriff
(2.078)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(2.347)
Koreanisch
(34)
Japanisch
(8)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager

Dynamic Cell and Microparticle Control via Optoelectronic Tweezers

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kinetic feasibility of nitroxyl reduction by physiological reductants and biological implications

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Nitric Oxide is Consumed, Rather Than Conserved, by Reaction with Oxyhemoglobin under Physiological Conditions

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Modulation of Nitric Oxide Bioavailability by Erythrocytes

Nitric Oxide Reaction with Red Blood Cells and Hemoglobin under Heterogeneous Conditions

Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

Regulation of Nitric Oxide Consumption by Hypoxic Red Blood Cells

Nitric Oxide Metabolism in Adults With Cyanotic Congenital Heart Disease

Antioxidant actions of nitroxyl (HNO)

Characterizing the PK/PD relationship for inhibition of capsaicin‐induced dermal vasodilatation by MK‐3207, an oral calcitonin gene related peptide receptor antagonist

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

Power grid aware timing analysis using S-parameter

Aktive Filter

Suchergebnisse filtern